Kezar Life Sciences Initiates Strategic Review Following FDA Setback on Autoimmune Hepatitis Trial

-Kezar Life Sciences, Inc. a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated di...

October 17, 2025 | Friday | News
Thermo Fisher and OpenAI Unite to Accelerate Drug Development with Frontier AI

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s p...

October 17, 2025 | Friday | News
MilliporeSigma to Acquire JSR Life Sciences’ Chromatography Business to Strengthen Biologics Purification Capabilities

Acquisition aims to strengthen company’s downstream process offering of advanced filtration and chromatography solutions JSR’s innovativ...

October 16, 2025 | Thursday | News
SCYNEXIS to Receive $22 Million from GSK as Phase 3 MARIO Study on Invasive Candidiasis Is Terminated

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis...

October 16, 2025 | Thursday | Regulatory
Corventum Secures FDA Clearance for IND of CVT-130 to Prevent Chemotherapy-Induced Cardiotoxicity

-Corventum, Inc., a new medicines company advancing novel therapies to make existing cancer treatments safer and more effective,  announced the clea...

October 15, 2025 | Wednesday | News
Xencor to Present Initial Phase 1 Data for XmAb819 Bispecific Antibody in Renal Cell Carcinoma at AACR-NCI-EORTC Conference

Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, announced the...

October 15, 2025 | Wednesday | News
Daiichi Sankyo Showcases Transformative ADC Data at ESMO 2025

Back-to-back Presidential Symposium presentations of ENHERTU from DESTINY-Breast11 and DESTINY-Breast05 demonstrate its potential to become a foundat...

October 14, 2025 | Tuesday | News
AstraZeneca at ESMO 2025: Advancing Oncology Across Breast, Bladder, Gastric, Lung, and Prostate Cancers

Presidential Symposium will feature DESTINY-Breast11 and DESTINY-Breast05, underscoring potential of ENHERTU® (fam-trastuzumab deruxtecan-nxki) in ...

October 14, 2025 | Tuesday | News
IDT and Hamilton Partner to Automate Next-Generation Sequencing Workflows for Global Genomic Research

To equip users with a complete next generation sequencing (NGS) solution from sample to answer, global genomics leader Integrated DNA Technologies (IDT),...

October 14, 2025 | Tuesday | News
Excellergy Launches with $70M Series A to Redefine Allergy Treatment with First-in-Class Trifunctional ECRIs

-Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid relief and complete control of alle...

October 14, 2025 | Tuesday | News
Bicara Therapeutics’ Ficerafusp Alfa Receives FDA Breakthrough Therapy Designation for HPV-Negative Head and Neck Cancer

Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patien...

October 14, 2025 | Tuesday | News
Shuttle Pharmaceuticals to Acquire Molecule.ai for $10 Million to Accelerate AI-Driven Drug Discovery

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage spec...

October 13, 2025 | Monday | News
ABLi Therapeutics Announces Positive Phase 2 Results for Risvodetinib in Untreated Parkinson’s Disease

ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosin...

October 10, 2025 | Friday | News
Greenwich LifeSciences Expands Phase III FLAMINGO-01 Breast Cancer Trial to Austria

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...

October 10, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close